Biotech Archives - Page 20 of 795

2 minute read

Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker

May 29, 5:56 PM

NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.

ANF

1 minute read

FDA
News

Castle Biosciences Announces Publication Of Study Demonstrating DecisionDx-SCC Test Identifies High-Risk SCC Patients Benefiting Most From ART

By Benzinga Newsdesk

May 29, 4:32 PM

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART

CSTL

1 minute read

Avidity Biosciences To Present Preliminary Data From Phase 1/2 FORTITUDE Trial Of AOC 1020 In People Living With Facioscapulohumeral Muscular Dystrophy At The 31st Annual FSHD Society International Research Congress

By Benzinga Newsdesk

May 29, 4:30 PM

Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™Avidity to host Volume 9 of

RNA

1 minute read

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

By Benzinga Newsdesk

May 29, 4:03 PM

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and

BBIO

1 minute read

GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024

By Benzinga Newsdesk

May 29, 4:03 PM

GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion

GLYC

2 minute read

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’

By Vandana Singh

May 29, 3:33 PM

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

IKNA

1 minute read

FDA Conditionally Approves Eli Lilly’s Thyroid Cancer Drug For Pediatric Patients With Certain Mutations

By Vandana Singh

May 29, 3:02 PM

Accelerated FDA approval for Eli Lilly's selpercatinib (Retevmo) in pediatric patients aged 2+ with advanced/metastatic thyroid cancer & solid tumors carrying RET mutations or fusions.

LLY

2 minute read

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study

By Vandana Singh

May 29, 2:47 PM

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

ARGX

2 minute read

Johnson & Johnson’s Drug Seltorexant Aces Late-Stage Depression Trial

By Vandana Singh

May 29, 12:55 PM

Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia.

JNJ

1 minute read

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca’s Drug

By Vandana Singh

May 29, 12:51 PM

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

AMGN